Diabetic Kidney Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Diabetic Kidney Disease Market Outlook

Thelansis’s “Diabetic Kidney Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Kidney Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Kidney Disease Overview

Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease (ESKD), affecting approximately 40% of patients with type 1 and 2 diabetes. Diabetic nephropathy is the primary cause of kidney disease in patients who require renal replacement therapy. The exact cause of diabetic nephropathy remains unknown; however, insulin resistance, genetics, hyperglycemia, and autoimmune processes may contribute. Hyperglycemia causes the production of reactive oxygen species, which activate various pathways, including protein kinase C, hexosamine, polyol, and advanced glycation end products (AGE). The resulting inflammation is characterized by increased levels of cytokines and chemokines such as IL-6, MCP-1, TGF-beta, and VEGF, leading to fibrosis, inflammation, and increased vascular permeability. Chronic tubular injury and fibrosis occur as a result of epithelial-mesenchymal cell transformation. Albuminuria results from podocytopathy, and proteinuria occurs due to systemic and intraglomerular hypertension. Proteinuria is a hallmark of diabetic nephropathy, and the absence of retinopathy makes diabetic nephropathy less likely in type 1 diabetes mellitus (T1DM) patients. Diabetic nephropathy patients risk developing acute kidney injury, and microalbuminuria is an independent risk factor for cardiovascular mortality. Most patients die from end-stage renal disease, and diabetic retinopathy is often associated with diabetic nephropathy. The prevalence of DKD in most type 2 diabetics - at any point in time - is approximately 30%-50%, and it was reported among US diabetic adults (>90% type 2).

• This prevalence ranged between 25% in patients younger than 65 years old to nearly 50% in age older than 65 years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: